Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Umoja Biopharma has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in January 2025.
Umoja Biopharma's investors include Temasek, Cormorant Asset Management, ARK Investment Management, DCVC Bio, Casdin Capital.
Umoja Biopharma is headquartered in Seattle, United States.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Umoja Biopharma is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Umoja Biopharma — Funding & Investors." VCBacked, January 14, 2025, https://www.vcbacked.co/company/umoja-biopharma. Accessed July 20, 2026.
VCBacked. (2025). Umoja Biopharma — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/umoja-biopharma
{{cite web |title=Umoja Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/umoja-biopharma |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated